BMS Makes Cuts to Clinical Development/Ops
November 8, 2013 | Bristol-Myers Squibb is making cuts to the clinical development/operations group it acquired when it picked up ZymoGenetics in 2010. The cuts are part of more extended cuts across the company, discontinuing broad based discovery work in hepatitis C, diabetes and neuroscience. Xconomy
Click here to log in.
Text Only 2000 character limit
Page 1 of 1